Key facts
- Notable investors include CMG SDIC Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Gantai Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Gantai Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gantai Pharmaceutical
Developer of pharmaceutical research solutions designed for drug discovery and preclinical evaluation purposes. The company's platform integrates compound screening, pharmacokinetic analysis, toxicology studies, and regulatory documentation support, enabling biotechnology firms and pharmaceutical enterprises to accelerate early-stage development, ensure compliance with clinical standards, and reduce time-to-market through comprehensive laboratory and data services.
- Sector
- Healthcare
- HQ
- China
- Founded
- 2021
- Employees
- 81
- Website
- 8jfw.com/
- Ownership
- Privately Held (backing)
Gantai Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gantai Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gantai Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.